mTORC1 and DNA‐PKcs as novel molecular determinants of sensitivity to Chk1 inhibition
Andrew J. Massey(Clatterbridge Cancer Centre NHS Foundation Trust), Nicola J. Curtin(Newcastle University)
Cited by 24
Related Papers
Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases
|British Journal of Pharmacology|2017|210
Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
|BMC Cancer|2014|110
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines
|Molecular Cancer Therapeutics|2009|94